Giant Fold Gastritis Induced by Epoprostenol Infusion in Patients With Pulmonary Arterial Hypertension

被引：3

作者：

Miura, Yohei ^{[1
]}

Kataoka, Masaharu ^{[3
]}

Chiba, Tomohiro ^{[2
]}

Inami, Takumi ^{[1
]}

Yoshino, Hideaki ^{[1
]}

Satoh, Toru ^{[1
]}

机构：

[1] Kyorin Univ, Sch Med, Dept Internal Med 2, Div Cardiol, Tokyo, Japan

[2] Kyorin Univ, Sch Med, Dept Pathol, Tokyo, Japan

[3] Keio Univ, Sch Med, Dept Cardiol, Tokyo, Japan

来源：

CIRCULATION JOURNAL | 2018年 / 82卷 / 10期

关键词：

Epoprostenol; Giant fold gastritis; Pulmonary arterial hypertension; Stomach barium examination; THERAPY;

D O I：

10.1253/circj.CJ-18-0349

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.

引用

页码：2676 / 2677

页数：2

共 50 条

[21] Staggered transition to epoprostenol from treprostinil in pulmonary arterial hypertension
Reisbig, KA
Coffman, PA
Floreani, AA
Bultsma, CJ
Olsen, KM
ANNALS OF PHARMACOTHERAPY, 2005, 39 (04) : 739 - 743
[22] Low Incidence of Catheter-Related Complications in Patients With Advanced Pulmonary Arterial Hypertension Undergoing Continuous Epoprostenol Infusion
Nagai, Toshiyuki
Kohsaka, Shun
Anzai, Toshihisa
Yoshikawa, Tsutomu
Fukuda, Keiichi
Sato, Toru
CHEST, 2012, 141 (01) : 272 - 273
[23] Effectiveness of epoprostenol in the management of pulmonary arterial hypertension: findings of an Australian retrospective chart review
Feenstra, John
Hopkins, Peter
Trotter, Michael
O'Brien, Kathy
INTERNAL MEDICINE JOURNAL, 2020, 50 (11) : 1377 - +
[24] Transition protocol from subcutaneous treprostinil to intravenous epoprostenol in deteriorating patients with pulmonary arterial hypertension
Mouratoglou, Sophia Anastasia
Patsiala, Anthoula
Feloukidis, Christos
Karvounis, Haralambos
Giannakoulas, George
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 306 : 187 - 189
[25] Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension
Tokunaga, Naoto
Ogawa, Aiko
Ito, Hiroshi
Matsubara, Hiromi
JOURNAL OF CARDIOLOGY, 2016, 68 (5-6) : 542 - 547
[26] Epoprostenol treatment for idiopathic pulmonary arterial hypertension in pregnancy
M J Garabedian
W F Hansen
E A Gianferrari
K Y Lain
R Y Fragneto
C L Campbell
D C Booth
Journal of Perinatology, 2010, 30 : 628 - 631
[27] A new epoprostenol formulation for the treatment of pulmonary arterial hypertension
Fuentes, Amaris
Coralic, Aida
Dawson, Kyle L.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (16) : 1389 - 1393
[28] Combination of bosentan with epoprostenol in pulmonary arterial hypertension:: BREATHE-2
Humbert, M
Barst, RJ
Robbins, IM
Channick, RN
Galié, N
Boonstra, A
Rubin, LJ
Horn, EM
Manes, A
Simonneau, G
EUROPEAN RESPIRATORY JOURNAL, 2004, 24 (03) : 353 - 359
[29] Epoprostenol discontinuation in patients with pulmonary arterial hypertension: a complex medical and social problem
Chebib, Nader
Cottin, Vincent
Taharo-Ag-Ralissoum, Martine
Chuzeville, Michel
Mornex, Jean-Francois
PULMONARY CIRCULATION, 2018, 8 (01)
[30] Inhaled Epoprostenol for the Treatment of Pulmonary Arterial Hypertension in Critically Ill Adults
Buckley, Mitchell S.
Feldman, Jeremy P.
PHARMACOTHERAPY, 2010, 30 (07): : 728 - 740

← 1 2 3 4 5 →